All Type of News
W 60 bil. sibutramine market steams up
The domestic sibutramine market valued at 60 billion won is set to heat up.
Following the country's forerunner Abbott’s Reductil, Hammi is rushing into the game selling its chemically modified sibutramine preparati...
Price determination of new leukemia drug to be delayed
The Ministry for Health, Welfare and Family Affair committee's decision on the price of Sprycel, a new drug for the disease, will be delayed, following its April 28 meeting.
The National Health Insurance Corp. sugg...
Prices of statin based hyperlipemic medicines to be reduced
The Health Review Insurance Agency says health insurance prices of statin based hyperlipemic agents, such as Pfizer’s Lipitor, will be reduced as a result of evaluating the economic effectiveness of those medicines, e...
30% of people aged 20 or older experience hair loss
28 percent of people in their 20s or older have experienced hair loss, according to a recent survey of 968 people throughout the country, conducted by “C-NEWS,'' an online company.
Of the respondents who have exper...
Kim Hyung-rae named NIH director
Kim Hyung-rae, incumbent chief of the Korea Center for Disease Control and Prevention, was named as the next director of National Institute of Health, the Ministry of Health, Welfare and Family Affair said on April 29...
Health insurance price of chemically modified Plavix to be determined
The Health Insurance Review Agency is now under negotiation to determine the insurance price of Daewoong’s Vixgrel, one of chemically modified Plavix (clopidogrel bisulfate), which have drawn keen interest from other ...
Restricted reimbursement of Crestor, Rivaro to be withheld
The Health Insurance Review Agency will reassess the health insurance coverage of Crestor (rosuvastatin) and Rivaro (pitavastatin), while the prices of other stastins are likely to be reduced.
The agency is also in...
Release of Xenical generics to be delayed
Pharmaceutical sources say the immediate launching of generic Xenical (orlistat) will take time as a local pharmaceutical firm has denied the launching news.
Recently, a domestic pharmaceutical bulk maker is said t...
Patent protection and patient access should be balanced
The excessive patent protection should be avoided as it may discourage the development of any innovative medicines as well as patient access, according to Park Sylvia a chief researcher at the Korea Institute for Heal...
Keunwha to step up strategic alliance with Sandoz Korea
Keunwha Pharm says it plans to strengthen its bilateral ties with Sandoz Korea.
Keunwha signed a licensing agreement with Sandoz Korea to distribute Felodipine tablets 5mg for treatment of essential hypertension.
...
